Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 277 No 7431 p726
16 December 2006

This article
Reprint   Photocopy

  Acrobat Reader


News summary

Related websites
No smoking resources


Give weight management advice to smokers who are trying to stop, NICE recommends

BSIP, Laurent/Science Photo Library

Smokers

Smokers who try to quit often gain weight

Health care professionals such as pharmacists should offer weight management advice to people who are trying to stop smoking, according to a new clinical guideline released this week by the National Institute for Health and Clinical Excellence. People often put on weight when giving up smoking, so the guideline says that health professionals should suggest services that advise on obesity prevention and management, as well as offer general advice on weight control and physical activity.

Alongside such lifestyle aspects of obesity prevention and management, “Guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children” incorporates recommendations previously offered by NICE on the use of orlistat (PJ, 17 March 2001, p350) and sibutramine (PJ, 20 October 2001, p541).

What differs from NICE’s previous technology appraisals of the two medicines is new recommendations on their use in children under specialist care (see Panel below).

Orlistat and sibutramine recommendations

• Drug treatment is recommended for adults and children only after dietary, exercise and behavioural approaches have been tried and evaluated

• For children under the age of 12 years, drug treatment is not recommended except in exceptional circumstances (where severe life-threatening comorbidities exist) and under specialist supervision

• For children aged 12 to 18 years, drug treatment is only recommended if physical or severe psychological comorbidities exist

• Orlistat and sibutramine should only be prescribed for obesity in children by a specialist multidisciplinary team

• Orlistat is restricted to adults with a body mass index (BMI) of 28 or more and with associated risk factors, or with a BMI >=30

• Sibutramine is restricted to adults with a BMI >=27 and other obesity-related risk factors such as type 2 diabetes, or with a BMI >=30

Back to Top


©The Pharmaceutical Journal